Profile
Sector:
HealthcareIndustry:
Health Information ServicesCountry:
United StatesIPO:
04 November 2020Website:
http://www.genedx.comNext earnings report:
30 October 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 1 min agoDividend
Analysts recommendations
Institutional Ownership
WGS Latest News
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the compensation committee of GeneDx's board of directors granted restricted stock units (“RSUs”).
The consensus price target hints at a 40.3% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does GeneDx Holdings Corp. (WGS) have what it takes to be a top stock pick for momentum investors? Let's find out.
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GeneDx (Nasdaq: WGS) today announced it will release financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024.
-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating utilization of rWGS services in neonatal intensive care units (NICUs) --
STAMFORD, Conn., May 22, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in two upcoming investor conferences in June: Jefferies Healthcare Conference - New York City, New York Fireside chat on Wednesday, June 5 at 9:00 a.m.
GeneDx Holdings Corp. (NASDAQ: WGS) held its Q1 2024 Earnings Conference Call on April 29, 2024 at 4:30 PM ET. Participants included Sabrina Dunbar, Katherine Stueland, and Kevin Feeley. Conference Call Participants included Daniel Brennan, Mark Massaro, Matthew Sykes, and Matthew Stanton. The operator thanked everyone for joining the call and stated that all participants were in a listen-only mode.
GeneDx Holdings Corp. (WGS) reported a quarterly loss of $0.33 per share, beating the Zacks Consensus Estimate of a loss of $0.68. This is an improvement from the loss of $2.82 per share reported a year ago.
GENEDX HOLDINGS (WGS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
What type of business is GeneDx Holdings?
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
What sector is GeneDx Holdings in?
GeneDx Holdings is in the Healthcare sector
What industry is GeneDx Holdings in?
GeneDx Holdings is in the Health Information Services industry
What country is GeneDx Holdings from?
GeneDx Holdings is headquartered in United States
When did GeneDx Holdings go public?
GeneDx Holdings initial public offering (IPO) was on 04 November 2020
What is GeneDx Holdings website?
https://www.genedx.com
Is GeneDx Holdings in the S&P 500?
No, GeneDx Holdings is not included in the S&P 500 index
Is GeneDx Holdings in the NASDAQ 100?
No, GeneDx Holdings is not included in the NASDAQ 100 index
Is GeneDx Holdings in the Dow Jones?
No, GeneDx Holdings is not included in the Dow Jones index
When was GeneDx Holdings the previous earnings report?
No data
When does GeneDx Holdings earnings report?
The next expected earnings date for GeneDx Holdings is 30 October 2024